Tabirafusp alfa

Multispecific antibody

Also known as KSI-101

Phase 3underway

Evidence outlook · registrational

Registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-02.

Company guidance: topline data expected December 2026 (NCT06990399; Kodiak Sciences Inc., 12 Nov 2026). “Phase 3 PEAK Study (KSI-101) – Pivotal Analysis 1 Topline Data Expected December 2026” Source ↗

Company guidance: regulatory filing expected second quarter of 2027 (Kodiak Sciences Inc., 12 Nov 2026). ““Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT06990399 · Kodiak Sciences Inc
2025-07-30 – 2027-11 · Macular Edema Secondary to Inflammation
What this study did
NCT06996080 · Kodiak Sciences Inc
2025-07-16 – 2027-08 · Macular Edema Secondary to Inflammation
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tabirafusp Alfa: this drugPhase 3Multispecific antibodyVEGF + IL-6not yet gradedNo reviewed efficacy summary
Tabirafusp Tedromer
Phase 3(overall)
Multispecific antibodyVEGF + IL-6Partial signal
NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28).

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tabirafusp alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 3Macular Edema Secondary to InflammationRecruiting
Est. primary completion 2027-02 · NCT06996080 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Macular Edema Secondary to InflammationRecruiting
Est. primary completion 2027-04 · NCT06990399 · CT.gov ↗

Company guidance: topline data expected December 2026 (Kodiak Sciences Inc., 12 Nov 2026). “Phase 3 PEAK Study (KSI-101) – Pivotal Analysis 1 Topline Data Expected December 2026” Source ↗

What to watch

See the full readout calendar ↗